We isolated a novel gene, termed MLZE, from a B16-BL6 cDNA library after subtraction of B16-F10 mRNA. Expression levels of mouse MLZE (mMLZE) increased in accordance with metastatic ability of B16 melanoma sublines. Human homolog of mMlze (hMlze) contained one leucine zipper structure and two potential nuclear localizing signals. Northern blot analysis of multiple human tissues showed that hMLZE was expressed primarily in trachea and spleen. We mapped the hMLZE gene (by fluorescence in situ hybridization) to 8q24.1-2, which contains the c-myc gene and is often amplified in malignant melanoma. Immunohistochemistry revealed that the number of hMlze-positive cases was significantly larger in Clark levels III, IV and V melanomas (6/11 = = = =55%) than in Clark levels I and II melanomas (2/15 = = = =13%). In two cases of hMlze-positive melanomas, the strength of hMlze staining increased substantially in the deep component of the tumor. Considering that melanomas above Clark level II are more metastatic than those below Clark level III, these findings suggested that MLZE is one of the genes whose expression is upregulated during the course of acquisition of metastatic potential in melanoma cells.
The incidence of cutaneous melanoma has increased at an alarming rate throughout the world. 1) Most thin melanomas can be cured by surgical excision. However, once metastases are formed, the disease is rarely curable and median survival time is approximately 6 months.
2) There seems to be a difference between thin and more advanced melanoma with respect to their clinical behaviors. Based on the observation of melanoma spread into the dermis, two phases of melanoma development have been described. 3) In the first phase, melanoma cells show intraepidermal proliferation and invasion of the papillary dermis by small nests. This phase is defined as the radial growth phase (RGP). In the second phase, melanoma cells gain the capacity to form an expansile nodule in the papillary dermis and infiltrate the reticular dermis and subcutaneous fat. This phase is defined as the vertical growth phase (VGP). By using a mouse model, VGP melanoma cells were shown to possess larger capability of metastasis than RGP melanoma cells. 4) In the course of tumor progression from RGP to VGP melanoma, genetic changes may occur that render melanoma cells metastatic. However, few such genetic changes have been identified yet. 5, 6) Among the commonly used parameters for the depth of tumor are Breslow thickness 7) and Clark invasion level.
3)
Breslow thickness measures the linear depth of tumor in millimeters. It disregards the histological architecture in and around the tumor. In contrast, Clark invasion level describes five invasion levels based on the histologic depth of tumor invasion. Melanomas of level I proliferate within the dermis. Level II melanomas infiltrate the papillary dermis as small nests. Level III melanomas form an expansile nodule that compresses the reticular dermis. Level IV and V melanomas infiltrate into the reticular dermis and subcutaneous fat, respectively. In clinical cases, melanoma cells of level III have been reported to behave in a more malignant manner than melanoma cells of level II. 8) Clark level II melanomas that carry no systemic metastasis at diagnosis yield a good survival of 96% after 8 years. In contrast, 8-year survival drops markedly to 76% when melanoma cells have already invaded to the depth of level III at diagnosis. Although Clark invasion level is a histologic classification, it is reasonable to con-sider that Clark level I and II melanomas correspond to RGP, and melanomas above Clark level II correspond to VGP.
In the present study, we attempted to characterize a novel gene, termed MLZE (Melanoma-derived Leucine Zipper, Extra-nuclear factor), as a marker for melanoma progression from RGP to VGP. To isolate MLZE, we examined a pair of B16 mouse melanoma cells, B16-F10 cells 9) and B16-BL6 cells. 10) B16-BL6 cells were obtained through six rounds of in vitro selection of B16-F10 cells. When injected into footpad, B16-BL6 cells metastasize to the lung at high frequency, whereas B16-F10 cells do not. With an improved method for constructing a subtracted cDNA library, 11) we have isolated a series of genes that were transcriptionally upregulated in B16-BL6 cells as compared with B16-F10 cells. [12] [13] [14] [15] MLZE was one such gene. Expression levels of mMLZE increased as B16 melanoma cells become more metastatic. Human homolog of mMlze (hMlze) contained one leucine zipper structure and two potential nuclear localizing signals (NLS). Immunohistochemistry revealed that the number of hMlze-positive cases were larger in Clark levels III, IV and V melanomas than in Clark levels I and II melanomas. In some cases, the strength of hMlze immunostaining increased substantially at the deep component of the tumor. hMLZE may be one of the genes whose expression is upregulated as malignant melanoma progresses from RGP to VGP.
MATERIALS AND METHODS
Cell lines F1, F10, and BL6 mouse melanoma cells were kindly provided by I. J. Fidler (The University of Texas, Houston, TX). Melan-a mouse melanocyte cells were kindly provided by D. C. Bennett (St. Georges Hospital Medical School, Cranmer Terrace, London, UK). 16) 293T human embryonic kidney cells and COS-7 monkey embryonic kidney cells were purchased from American Type Culture Collection (Manassas, VA). Melan-a cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum and 200 nM 12-O-tetradecanoylphorbol-13-acetate (TPA). The remainder were maintained in DMEM supplemented with 10% fetal calf serum. Screening of cDNA and genomic DNA libraries Preparation of subtracted cDNA library was performed as described previously. 11) To obtain hMLZE, a human cDNA library was prepared from HeLa cells using the λZAP-cDNA synthesis kit (Stratagene, La Jolla, CA). A total of 1×10 6 clones were screened with a radiolabeled EST clone AW276035 which was obtained by polymerase chain reaction (PCR), and the insert cDNAs were excised from positive clones in vivo into pBluescript SK(−) vector. A human placental genomic DNA library was purchased from TaKaRa (Ohtsu) and a total of 1×10 6 clones were screened with the radiolabeled hMLZE coding region.
In vitro transcription/translation The TNT T7 quick coupled transcription-translation system (Promega, Madison, WI) was used according to the manufacturer's instructions. Northern blot analysis Total RNA was prepared using a guanidine thiocyanate/CsTFA method. For northern blot analysis, 20-30 µg of total RNA was separated by denaturing gel electrophoresis and transferred to Biodyne A (Pall, Port Washington, NY). Human multiple tissue northern blots were purchased from Clontech, Palo Alto, CA. The hMLZE coding region, amplified by PCR with the primer set F-hMLZE (5′-ATGCCCTCCATGTTGGAACG-3′) and R-hMLZE (5′-TTAGGCCTCAGCCAGCTGCT-3′), was radiolabeled with [α-32 P]dCTP using a Random Primer DNA Labeling Kit (TaKaRa). Fluorescence in situ hybridization (FISH) The partial genomic DNA of hMLZE was obtained by screening a human placental genomic DNA library with the radiolabeled hMLZE coding region as a probe. Positive clones were digested with EcoRI and a 7-kb fragment was obtained. We confirmed that the fragment contained the sequence of nucleotides 1613-1735 of hMLZE cDNA by PCR with the primer set F-G (5′-AGTACGAAATTTC-CGAAATGGTAGG-3′) and R-G (5′-CTGGTTTTAAC-TTCATATCATTGGA-3′). FISH analysis of R-banded human chromosomes was performed as described previously. 17) Briefly, 150 ng of biotin-labeled genomic DNA probe was hybridized to metaphase chromosome spreads. For fluorochrome detection, the slides were incubated with fluorescein isothiocyanate (FITC)-conjugated avidin (Vector Laboratories, Burlingame, CA) and then washed. The FITC signals were amplified by incubation with biotinconjugated goat anti-avidin antibody (Vector Laboratories) followed by incubation with FITC-conjugated avidin. Preparations were counterstained with propidium iodide and observed under a laser scanning microscope (Zeiss LSM410).
Generation of anti-hTib23 antibody
A modified pET28a vector (Novagen, Madison, WI) was constructed by replacing the multiple cloning sites of pET28a with that of pET32a (Novagen) at the BamHI-TthIII sites. This modification allowed the insertion of cDNA by way of the BamHI-NotI sites. Using the pBluescript SK(−) vector containing the full-length hMLZE, PCR was performed with the following set of primers: F-Bam-hMLZE, 5′-GGA-TCCATGCCCTCCATGTTGGAACG-3′; R-Not-hMLZE, 5′-GCGGCCGCTTAGGCCTCAGCCAGCTGCT-3′. The PCR-amplified cDNA fragment was subcloned into the pT7 Blue vector (Novagen). The amplified cDNA fragment was excised and ligated into the modified pET28a vector by way of the BamHI-NotI sites. The plasmid was transformed to BL21-CodonPlus (Stratagene) and expres-sion of the 6 His-tagged hMlze was induced with 0.2 mM isopropylthiogalactoside. The bacteria were lysed by sonication and hMlze tagged with 6 His was extracted from the insoluble pellet with 8 M urea, 0.5 M NaCl, 5 mM imidazole and 20 mM Tris-HCl (pH 8.0). Extracted protein was applied to Talon resin and eluted with excess imidazole. White rabbits were immunized with the purified protein to produce polyclonal antibody. Western blot analysis Whole cell lysates were prepared by adding 10 times the volume of lysis buffer (50 mM Tris-HCl [pH 8.0], 250 mM NaCl, 0.1% NP-40, 1 mM phenylmethylsulfonyl fluoride (PMSF)) to a pellet of 1×10 6 cells. The lysate (50 µg of protein) was boiled for 5 min, separated on 10% SDS-polyacrylamide gel electrophoresis (PAGE) gel and transferred onto Immobilon membrane (Millipore, Eschborn, Germany). The membrane was incubated with rabbit anti-hMlze polyclonal antibody at 1:200 dilution or rabbit anti-GFP polyclonal antibody (MBL, Nagoya) at 1:1000 dilution for 1 h, then incubated with horseradish peroxidase-conjugated antirabbit IgG antibody at 1:1000 dilution (MBL). For detection of the immunocomplex, Renaissance chemiluminescence reagent (Dupont/NEN, Boston, MA) was used. Immunohistochemistrty Formalin-fixed and paraffinembedded specimens were deparaffinized and hydrated in a graded series of alcohols. Endogenous peroxidase was quenched in phosphate-buffered saline containing 0.3% peroxide. The samples were incubated with anti-hMlze polyclonal antibody at 1:200 dilution or anti-c-Myc monoclonal antibody (Ab-1, Oncogene Science, Cambridge, MA) at 1:100 dilution for 2 h at room temperature, followed by incubation with horseradish peroxidaseconjugated anti-rabbit IgG antibody or anti-mouse IgG 1 antibody (MBL) for 1 h at room temperature. Thereafter, the final products were visualized using diaminobenzidine (DAB) or aminoethylcarbazole (AEC) as a substrate for peroxidase. Negative controls were run with using nonimmunized rabbit IgG instead of the primary antibody. The slides were counterstained with Mayer's hematoxylin. Immunocytochemistry Cells were plated on chamber culture slides (Becton Dickinson, Franklin Lakes, NJ). Cells were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS), permeabilized with 0.1% Triton X-100 in PBS, blocked with 2% bovine serum albumin (BSA) in PBS, incubated with anti-hTib23 antibody at 1:200 dilution at room temperature for 2 h, and stained with FITClabeled anti-rabbit IgG. Cells were visualized with using a confocal laser scanning microscope (Zeiss LSM410). In vivo analysis of GFP fusion proteins We previously reported a modified pEGFP-C1 vector (Novagen), termed pEGFP3B. 18) This vector allowed the cDNA insert to be fused to the 3′ end of EGFP by way of AscI-NotI sites. We also reported a modified pEGFP3B vector, termed pEGFP3 vector. This vector was constructed by insertion of an in-frame stop codon between EGFP and the AscI site so that it produced EGFP protein and could serve as a control vector for pEGFP3B vector. Using the pBluescript SK(−) vector containing the full-length cDNA for hMLZE as a template, PCR was performed with the following sets of primers: F-Asc-hMLZE (5′-GGCGCGCCGATGCCCT-CCATGTTGGAACG-3′) and R-Not-hMLZE (5′-GCGGC-CGCTTAGGCCTCAGCCAGCTGCT-3′) for pEGFP3B-hMLZE; F-Asc-NLS2 (5′-GGCGCGCCGGAGAGTCT-CAGAGTGAAGAA-3′) and R-Not-TAA-NLS2 (5′-GCG-GCCGCTTAAATGGCTTTCTCCTTGATAACCA-3′) for pEGFP3B-hMLZE-NLS2; F-Asc-hMLZE and R-Not-TAA-∆N (5′-GCGGCCGCTTATTCGGAAATTTCGTACTCAT-3′) for pEGFP3B-hMLZE-∆N; F-Asc-∆C (5′-GGCGCGC-CGATGGTAGGCTACTGTGCTGC-3′) and R-Not-hMLZE for pEGFP3B-hMLZE-∆C. PCR-amplified DNA fragments were subcloned into the pT7 Blue vector. After amplification, cDNA fragments were excised and ligated into the pEGFP3B vector in-frame by way of the AscINotI sites. The following are the amino acid (a.a.) residues of hMlze protein in each vector intended to be fused to EGFP protein: a.a. residues 1-508, pEGFP3B-hMLZE; a.a. residues 196-227, pEGFP3B-hMLZE-NLS2; a.a. residues 1-246, pEGFP3B-∆N; a.a. residues 247-508, pEGFP3B-∆C.
293T cells and COS-7 cells were transiently transfected using Lipofectamine transfection reagent (Gibco-BRL, Gaithersburg, MD). The cells were cultured in 35 mm glass-bottomed culture dishes for 24 h after transfection and then observed in vivo through an inverted laser scanning microscope (Zeiss LSM410). Human malignant melanoma and nevus samples Twenty-six patients with malignant melanoma and five patients with nevus underwent surgical excision in the Osaka University Hospital. Surgical samples were fixed in formalin and embedded in paraffin.
RESULTS
Isolation of mouse and human MLZE cDNAs Among the cDNA clone pool obtained after subtraction of the B16-BL6 cDNA library with B16-F10 mRNA, 12) we isolated a mouse novel gene that we termed mouse MLZE (mMLZE). Expression of mMLZE mRNA was detected easily in both B16-F10 and B16-BL6 cells, but it was three-fold stronger in B16-BL6 cells. In contrast, the expression of mMLZE was below the limit of detection in melan-a and B16-F1 cells (Fig. 1) . Since melan-a cells are non-tumorigenic, and since B16 sublines, F1, F10 and BL6 cells acquire larger potentials for metastasis in this order, expression levels of mMLZE correlated well with metastatic potentials of melanoma cells. By screening a B16-BL6 cDNA library, we isolated a 2191-bp-long clone. This clone appeared to carry an almost full-length cDNA for mMLZE, because the mMLZE transcript was detectable as a single band of about 2.4 kb in B16-BL6 cells (Fig. 1) . mMLZE contained an open reading frame of 1570 nucleotides (DDBJ/GenBank/EMBL database accession number AB042406) and was supposed to encode a protein of 468 amino acid residues.
Homology searching at the National Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih. gov/BLAST/) revealed that the coding region of mMLZE was 79.2% and 81.2% homologous to human EST clones AW276035 and AI05243, respectively. We speculated that these EST clones might constitute a part of the human homolog (hMLZE) of mMLZE. A HeLa cDNA library was screened for cloning of a full-length hMLZE by using AW27635.1 DNA fragment as a probe. Of the positive clones obtained, the longest was 2761-bp long (DDBJ/ GenBank/EMBL database accession number AB042405). We estimated it to be nearly full-length, since northern blot analysis showed that the transcript size of hMLZE is about 2.8 kb in HeLa cells (data not shown).
The clone contained a 1527 bp open reading frame which encoded a putative protein of 508 amino acid residues with a calculated molecular mass of 57 kDa (Fig. 2) . The sequence surrounding the proposed starting codon partially matched the consensus for a eukaryotic translation initiation site. 19) A protein of approximately 60 kDa was generated when the longest clone was subjected to in vitro transcription-translation analysis (data not shown), indicating that the predicted start codon was functional in vitro. The predicted protein showed no obvious homology to previously identified proteins. However, particular structural features were identified in the deduced amino acid sequence of hMlze. The N-terminal region was rich in basic amino acids. In particular, amino acid residues 133-151 (KRKLLDPEPSFLKECRR) and 201-218 (KKALTLQKGMVMAYKRK) matched the bipartite nuclear localizing signal (NLS) motif.
20) The C-terminal region contains a region rich in leucine, including a leucine zipper structure at amino acid residues 392-413. β-actin Tissue distribution and chromosomal localization of hMLZE The tissue distribution of hMLZE mRNA was determined by northern blot analysis of a multiple human tissue blot. A transcript of approximately 2.8 kb was detected predominantly in trachea and spleen (Fig. 3) .
The chromosomal location of hMLZE gene was determined by FISH analysis. As shown in Fig. 4 , specific FISH signals generated from a biotinylated hMLZE genomic DNA fragment were observed at the teleromeric region of the long arm of human chromosome 8. No other reproducible signal was observed on metaphase chromosomes. Thus, we concluded that hMLZE gene maps to the 8q24.1-2 region. Cytoplasmic localization of hMlze By using the antisera against recombinant hMlze, western blot analysis was performed on extracts of 293T cells which had been transiently transfected with pEGFP3 empty vector or pEGFP3B-hMLZE vector. Expression of GFP alone and GFP-tagged hMlze in 293T cells was confirmed with anti-GFP antibody (Fig. 5A) . After stripping, the blot was reacted with the anti-hMlze antisera. GFP-tagged hMlze alone was recognized with the antisera. This recognized band disappeared when the reaction was subject to competition with an excess amount of the antigenic recombinant protein (data not shown). Thus, we judged that the antisera could be used as a specific antibody for hMlze.
When the B16-BL6-metastasizing colony was stained with anti-hMlze antibody, cytoplasmic staining was
293T
COS-7 observed in B16-BL6 cells (Fig. 5B) . Cultured B16-BL6 cells also showed a cytoplasmic staining (Fig. 5B) . The staining in BL6 cells was abolished by the excess of antigenic recombinant hMlze protein (data not shown). Although the N-terminal region of hMlze contains two potential bipartite NLS, hMlze appeared to be located in the cytoplasm.
To examine whether the potential bipartite NLS of hMlze were active in living cells, we ligated GFP cDNA upstream from the translation start codon in an in-frame manner and introduced the resulting plasmid construct into 293T and COS-7 cells. Consistent with the results of immunostaining, GFP-fused hMlze was located diffusely in the cytoplasm of living cells (Fig. 6) . Then, the subregions of hMlze polypeptide of interest were tagged to GFP and subcellular localization was examined in the same manner. First, hMlze was divided into two; the Nterminal half and C-terminal half of the protein. The C-terminal half of hMlze containing a leucine zipper (GFPfused hMlze-∆C in Fig. 5 ) was distributed equally in the cytoplasm and nucleus, whereas the N-terminal half of hMlze containing two potential bipartite NLS (GFP-fused hMlze-∆N in Fig. 5 ) was located diffusely in the cytoplasm (Fig. 5C ). Then the NLS sequence was examined for subcellular localization. GFP-fused hMlze-NLS2, the bipartite NLS second from the N-terminus of hMlze, was
Normal skin Nevus Melanoma
Rabbit serum Mlze Fig. 7 . Immunohistochemical staining of normal skin, nevus and melanoma. Samples were probed with anti-hMlze antibody (lower panel) or non-immunized normal IgG for control staining (upper panel). All samples were counterstained with hematoxylin. Melanocytes in the normal skin (arrow) and nevus cells were negative for staining, whereas melanoma cells showed cytoplasmic staining (original magnification ×10 for normal skin and ×40 for nevus and melanoma).
predominantly located in the nucleus. These data suggest that the potential bipartite NLS of hMlze was functional but other regions present in the N-terminal half portion prevented hMlze from entering the nucleus. Expression of hMlze and c-Myc in RGP and VGP melanoma Expression of hMlze was examined by immunohistochemistry in normal skin, nevi, and melanomas. Paraffin-embedded tissue samples were stained with anti-hMlze antibody and counterstained with hematoxylin. Control samples from each section were run using non-immunized rabbit serum instead of the primary antibody and counterstained with hematoxylin. Within normal skin, melanocytes were negative for hMlze (Fig. 7) , which might be consistent with the fact that the hMLZE mRNA expression was not detectable in melan-a cells (Fig. 1) . Nevus cells were negative for hMlze in five cases with intradermal nevus (Fig. 7) . hMlze expression was then examined in clinical cases of malignant melanoma. Clinical profiles are summarized in Table I . Based upon Clark invasion level, twenty-six patients were divided into two groups; RGP melanoma group and VGP melanoma group. The former group was made up of fifteen cases of Clark I and II, while the latter was made up of eleven cases of Clark III, IV and V. In the VGP melanoma group, six out of eleven cases showed an hMlze-positive staining. In contrast, only two out of fifteen cases belonging to RGP melanoma group were positive for hMlze. The ratios of numbers of patients positive versus negative for hMlze were 6/11 and 2/15 in the VGP and RGP melanoma group, respectively. The difference between the two groups was significant by Fisher's exact and χ 2 tests (P<0.05). c-myc is one of the genes whose expression has been examined intensively in malignant melanoma. 21, 22) In addition, we found that the c-myc gene is located in the neighborhood of the hMLZE gene. Hence, we examined whether c-Myc was also positive in the hMlze-positive melanoma samples. Other sections of melanoma samples were stained with anti-c-Myc antibody. In the VGP melanoma group, four out of eleven cases showed c-Myc-positive staining. In contrast, three out of fifteen cases belonging to the RGP melanoma group were positive for c-Myc. The ratios of numbers of patients positive versus negative for c-Myc were 4/11 and 3/15 in the VGP and RGP melanoma group, respectively. The difference between the two groups was not significant by Fisher's exact and χ 2 tests (P>0.05). Histologic distribution of hMlze and c-Myc immunoreactivity in melanoma spread Immunoreactivity for hMlze and c-Myc was examined at each anatomic level of the melanoma spread; epidermis level, papillary dermis level, reticular dermis level and subcutaneous fat level. The results are summarized in Table I . None of six hMlze-positive cases (cases 16, 18, 19, 21, 24 and 26) in the VGP melanoma group showed a decrease in immunoreactivity to hMlze within the lower invasive component of the tumor. Moreover, in cases 24 and 26, the strength of hMlze staining increased at the lower invasive component of the tumor (case 24 in Fig. 8 ; case 26, data not shown). By contrast, in case 19, c-Myc-staining substantially decreased at the lower invasive component of the tumor, although it was detectable in melanoma cells resident in the upper component of the tumor (Fig. 8) .
DISCUSSION
In an attempt to seek novel genes that are expressed differently between B16-F10 and B16-BL6 cells, we applied a method for constructing subtracted cDNA libraries. After subtraction of the B16-BL6 cDNA library with B16-F10 mRNA, we isolated a novel cDNA, mMLZE. Expression levels of mMLZE increased as B16 melanoma cells become more metastatic, and reached a peak in B16-BL6 cells (Fig. 1) . Human homolog of MLZE (hMLZE) was isolated from a HeLa cDNA library. Among various systemic organs, hMLZE was expressed predominantly in trachea and spleen, suggesting a limited expression of hMLZE gene under physiological conditions. The hMlze protein contains a leucine zipper structure and two potential NLS. These structural features of hMlze may suggest that hMlze functions as a transcription factor in the nucleus. In fact, hMlze appeared to be present mainly in the cytoplasm under standard culture conditions. However, there is a possibility that hMlze may enter the nucleus under certain physiologic or pathologic conditions, since the bipartite NLS of hMlze were functional in nuclear translocation.
Both the hMLZE and c-myc genes are located in chromosome 8q24.1-2 region. The genomic region including 8q24.1-2 is amplified frequently not only in cutaneous melanoma, 23) but also in various cancers including ovarian cancer, 24) brain tumor, 25) breast cancer, 26) and lung cancer. 27) Since there was a possibility that hMLZE gene was amplified together with c-myc, we compared the expression of hMlze with that of c-Myc in human melanoma samples. Two of seven (29%) c-Myc positive samples coexpressed hMlze, while hMlze is expressed in about 30% of all melanoma samples examined in this study. In addition, the histologic distribution of immunoreactivity to hMlze was distinct from that to c-Myc when double-positive samples (case 19 in Fig. 8 ; case 26, data not shown) were examined. The DNA copy number of mouse and human MLZE was also investigated by Southern hybridization. However, no change in DNA copy number of MLZE gene was detected in mouse B16 sublines. Similar results were obtained with human lung cancer tissue, which expressed high levels of hMLZE (Watabe et al., unpublished data). Upregulation of hMlze might not depend upon gene amplification, different from the case of c-Myc. 28) Although the function of Mlze remains unknown, its expression profiles and chromosomal localization suggested an involvement of Mlze in melanoma progression. In order to examine hMlze expression in human melanoma lesions and its correlation with malignant potentials, we divided malignant melanoma samples into two groups; RGP and VGP melanoma groups. Specimens of both groups were subjected to immunohistochemistry with antihMlze. The expression of c-Myc has been intensively investigated in melanocytic lesions. 21, 22) For comparison, specimens were also stained with c-Myc. The VGP melanoma group showed a positive immunoreactivity to hMlze at a significantly larger frequency than the RGP melanoma group. In contrast, there was no significant difference between the two groups in the frequency of positive immunoreactivity to c-Myc. The number of c-Mycpositive cases was smaller than that of hMlze-positive cases in VGP groups. In addition, we examined hMlze expression in nevus cells. Although nevus cells were reported to be often positive for c-Myc, 22) all nevus specimens examined were negative for hMlze. Taken together, hMlze appeared to be more specific for malignant melanoma cells than c-Myc, and hMlze-specificity was stronger in advanced melanoma cells.
Several markers, such as HMB45 and c-Myc, are used to help diagnosis of malignant melanomas. 29) HMB45 is selective for malignant melanoma, while c-Myc is a broad marker for a number of human malignancies. HMB45 often fails to detect the lower invasive component of melanoma. 30) In fact, the strength of c-Myc-staining decreased substantially in the lower invasive component of case 19 (Fig. 8) . We examined whether immunoreactivities for hMlze changed according to the invasive levels of melanoma cells. We did not find the strength of hMlze-staining to be decreased within the invasive descent of the melanoma spread. On the contrary, immunoreactivity for hMlze increased remarkably as melanoma cells spread deeper into the dermis in case 24. These findings suggested that hMlze expression was upregulated in the course of melanoma progression from RGP to VGP. The anti-hMlze antibody could be useful to detect melanoma cells invading deepest into the dermis.
In the previous study we characterized annexin VII as a marker for less invasive phenotype of melanoma. 15) This gene was isolated from an F10 cDNA library subtracted with BL6 mRNA. In the present study, we isolated a novel gene, termed MLZE, from BL6 cDNA library subtracted with F10 mRNA. Immunohistochemistry of human melanoma lesions suggested that Mlze was upregulated in the course of melanoma progression from RGP to VGP.
Although both annexin VII and Mlze were isolated from a cDNA library of B16 sublines, expression profiles of both genes were closely related to malignant progression of human melanoma. Further analysis of our subtracted libraries should lead to a better understanding of the genetic alterations during melanoma progression.
